The North West Fund
VC Fund
Warrington, United Kingdom
The North West Fund is a £155m evergreen investment fund established to provide debt and equity funding to small and medium sized enterprises in the North West of England. The Fund will address an identified gap in the lending, venture capital and private equity markets.The Fund is managed by North West Business Finance Limited, an independentprivate sector company.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries The North West Fund invests in
Stages The North West Fund invests in
Countries The North West Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $131k–$262k
- Series A
- $786k–$4.1M
- Series B
- $1.3M–$2.5M
Investment Focus
Industry
- Health Care 4 (33%)
- Biotechnology 4 (33%)
- Medical Device 4 (33%)
- Pharmaceutical 2 (17%)
- Mobile 1 (8%)
Stage
- Seed 4 (33%)
- Series A 2 (17%)
- Series B 2 (17%)
- Funding Round 2 (17%)
- Series C 1 (8%)
Country
- United Kingdom 8 (67%)
- United States 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cliff Maylor
Co-Founder and Chief Executive Officer
|
Co-Founder and Chief Executive Officer | Total investments: 0 | Find email | |
Malcolm Edge
Chairman
|
Chairman | Total investments: 0 | Find email | |
Michael Prince
Director
|
Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ulemco
|
Ulemco specializes in the development of hydrogen technologies that allows commercial vehicles to run off hydrogen. | $6.3M / Venture - Series Unknown / May 15, 2024 | |
CynapseDx
|
CynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as alzheimer or parkinson disease. They engage in oligomeric and aggregated forms of protein biomarkers and have demonstrated that our assays can measure these forms of biomarkerproteins, when testing real patient blood samples. | $301K / Aug 05, 2015 | |
Perfectus Biomed
|
They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client’s need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing.They appreciate that not all products are appropriate forstandard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products.They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce. | $262K / Seed / Apr 28, 2015 | |
RealityMine
|
RealityMine enables many of the world’s largest market research and media organisations to monitor real consumers on multiple devices, across all major platforms, revealing unique insights from real life consumer behaviour. The firm’s RealityMeter can be deployed across Android, iOS and desktop platforms, and is deployed by leading panel owners andresearch clients across five continents. RealityMine is headquartered in Manchester, England, with offices in London and Sydney. | $2.5M / Series B / Jan 16, 2015 | |
Videregen
|
Videregen’s goal is to offer the world’s first commercially available organ replacement products to address the chronic shortage of organs for transplantation. Formed in 2011 as a spin-out from Northwick Park Institute of Medical Research in London, it uses its proprietary technology to produce biological scaffolds to which a patient’s own stemcells are added, creating a bespoke organ replacement.Initially focused on diseases of the trachea and bowel, Videregen aims to develop the world’s first commercially available organ replacements for these conditions, reducing healthcare costs and improving the quality of life for patients. | $4.1M / Series A / Oct 24, 2014 | |
Altabrisa Group
|
The Altabrisa Group is a consultancy company in pharmaceuticals, medical devices, and biotechnology. They offer first-rate GXP (GCP, GLP, and GMP) consulting services. Their purpose is to provide a tailored approach and global delivery. They are a small consulting and management firm. Southern Pharma Consultants provides a broad range of qualityand regulatory compliance consulting services. They also offer consulting services such as quality and compliance audits, pre-approval inspection preparation, process, utility, computer, and facility validation, as well as CMC analytical, formulation, manufacturing, and quality services. | $1.2M / Series C / Apr 08, 2014 | |
|
RealityMine
|
RealityMine enables many of the world’s largest market research and media organisations to monitor real consumers on multiple devices, across all major platforms, revealing unique insights from real life consumer behaviour. The firm’s RealityMeter can be deployed across Android, iOS and desktop platforms, and is deployed by leading panel owners andresearch clients across five continents. RealityMine is headquartered in Manchester, England, with offices in London and Sydney. | $786K / Series A / Jul 24, 2013 | |
|
Perfectus Biomed
|
They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client’s need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing.They appreciate that not all products are appropriate forstandard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products.They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce. | $131K / Seed / Jun 19, 2013 | |
Cerus Endovascular
|
Cerus Endovascular Ltd designs and develops interventional neuroradiology devices and delivery systems. The company develops e-clipse, an aneurysm occlusive device that addresses the current neurovascular aneurysm procedures attempted by surgical clipping, minimally invasive metal coils and liquid embolics. The company was founded in 2011 and isbased in Oxford, United Kingdom. | Seed / Jun 06, 2013 | |
Connect Childcare
|
Connect Childcare are proud to be helping nurseries with their fully integrated management, observation & communication software systems. Our products are making nurseries more efficient so that their staff can spend more time developing the children in their care. | $177K / Seed / Sep 12, 2012 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does The North West Fund invest in?
The North West Fund invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is The North West Fund's check size?
The North West Fund typically joins rounds of $131k–$262k at Seed, $786k–$4.1M at Series A and $1.3M–$2.5M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds The North West Fund participates in.
How do I contact The North West Fund?
Public channels for The North West Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The North West Fund?
The team at The North West Fund includes Cliff Maylor (Co-Founder and Chief Executive Officer), Malcolm Edge (Chairman) and Michael Prince (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
